MESENCHYMAL CHONDROSARCOMA. AN ANALYSIS OF PATIENTS TREATED AT A SINGLE INSTITUTION

Marilena Cesari¹, Franco Bertoni², Patrizia Bacchini², Mario Mercuri³, Emanuela Palmerini¹, and Stefano Ferrari¹

¹Chemotherapy, ²Pathology, ³5th Division of Orthopedic Surgery, Department of Musculoskeletal Oncology, Istituti Ortopedici Rizzoli, Bologna, Italy

Background: We analyzed clinical and treatment-related factors influencing the outcome of patients with mesenchymal chondrosarcoma (MC). Twenty-six patients (median age, 31 years) were identified using the Tumor Center and Chemotherapy Department database of the study institute.

Methods: Patients received surgery (24 patients) and/or radiotherapy (5 patients), and chemotherapy (12 patients).

Results: After a median follow-up of 48 months (7-237 months) 10 patients were alive. The 10-year overall survival (OS) was 27% in those who achieved complete surgical remission and 0% in those who did not (P = 0.0007). A worse 10-year probability of OS was observed in patients who were metastatic at presentation (metastatic 0%, localized 31%, P = 0.02), in patients with soft tissue MC (soft tissue MC 0%, bone MC 29%, P = 0.06) and in hemangiopericytoma-like MC (hemangiopericytoma-like MC 0%, Ewing's-like MC 33.5%, P = 0.9). In those patients who achieved complete surgical remission, the 10-year DFS was 76% for those who received chemotherapy and 17% for those who did not (P = 0.008).

Conclusions: Our experience confirmed the importance of complete surgical remission in MC treatment and suggests that the addition of chemotherapy should offer a benefit in terms of DFS. Due to the rarity of MC, multicentre studies are needed to identify the most active chemotherapy regimen.

Key words: chemotherapy, mesenchymal chondrosarcoma, radiotherapy.

Acknowledgments: The authors thank Alba Balladelli, BA, for revision of the manuscript and Cristina Ghinelli for graphics.

Correspondence to: Stefano Ferrari, MD, Sezione di Chemioterapia, Istituti Ortopedici Rizzoli, Via Pupilli 1, 40136 Bologna, Italy. Tel +39-051-6366411; fax +39-051-636627; e-mail stefano.ferrari@ior.it

Received January 19, 2007; accepted April 24, 2007.